• About us
• Contact

Advertisement

Organisation › Details

Tempus (Group)

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. *

 

	Start	2015-01-01 established
	Industry	personalised medicine / precision medicine
	Industry 2	bioinformatics (biological software and databases)
	Person	Lefkofsky, Eric (Tempus Labs 202003 CEO + Founder)
	Person 2	Fukushima, Ryan (Tempus 202408 COO + Pathos CEO)
	Region	Chicago, IL
	Country	United States (USA)
	City	n. a. Chicago, IL
		Address record changed: 2024-09-04
Basic data	Employees	F: 1,001 to 5,000 (2020-12-10)
		* Document for »About Section«: Tempus AI, Inc.. (9/4/24). "Press Release: Tempus Announces Real World Data Collaboration with BioNTech". Chicago.
		Record changed: 2024-09-04

Advertisement

More documents for Tempus (Group)

• [1] Tempus AI, Inc.. (9/26/24). "Press Release: Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-world Datasets and Biological Model Systems in Oncology Research and Development". Chicago, IL....
• [2] Tempus AI, Inc.. (9/12/24). "Press Release: Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients". Chicago, IL....
• [3] Tempus AI, Inc.. (9/4/24). "Press Release: Tempus Announces Real World Data Collaboration with BioNTech". Chicago....
• [4] Tempus AI, Inc.. (8/28/24). "Press Release: Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference". Chicago, IL....
• [5] Tempus Labs, Inc.. (2/28/23). "Press Release: Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development"....
• [6] Tempus Labs, Inc.. (2/23/23). "Press Release: Tempus Announces New Multi-omics Collaboration with Actuate Therapeutics"....
• [7] Tempus Labs, Inc.. (10/20/22). "Press Release: Tempus Announces $275 Million in Funding"....
• [8] GSK plc. (10/18/22). "Press Release: GSK Announces Expanded Collaboration with Tempus in Precision Medicine to Accelerate R&D". London....
• [9] Tempus Labs, Inc.. (1/13/21). "Press Release: Tempus Announces Companion Diagnostic Collaboration with A2 Biotherapeutics"....
• [10] Tempus Labs, Inc.. (12/10/20). "Press Release: Tempus Announces $200 Million Series G-2 Financing"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.